Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 172
Filtrar
5.
J Investig Allergol Clin Immunol ; 32(6): 471-478, 2022 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-34489228

RESUMO

BACKGROUND AND OBJECTIVES: Asthma is a chronic inflammatory condition of the airways with a complex pathophysiology. Stratification of asthma subtypes into phenotypes and endotypes should move the field forward, making treatment more effective and personalized. Eosinophils are the key inflammatory cells involved in severe eosinophilic asthma. Given the health threat posed by eosinophilic asthma, there is a need for reliable biomarkers to identify affected patients and treat them properly with novel biologics. microRNAs (miRNAs) are a promising diagnostic tool. The aim of this study was to identify serum miRNAs that can phenotype asthma patients. METHODS: Serum miRNAs of patients with eosinophilic asthma (N=40) and patients with noneosinophilic asthma (N=36) were evaluated using next-generation sequencing, specifically miRNAs-seq, and selected miRNAs were validated using RT-qPCR. Pathway enrichment analysis of deregulated miRNAs was performed. RESULTS: Next-generation sequencing revealed 15 miRNAs that were expressed differentially between eosinophilic and noneosinophilic asthma patients, although no differences were observed in the miRNome between atopic and nonatopic asthma patients. Of the 15 miRNAs expressed differentially between eosinophilic and noneosinophilic asthma patients, hsa-miR-26a-1-3p and hsa-miR-376a-3p were validated by RT-qPCR. Expression levels of these 2 miRNAs were higher in eosinophilic than in noneosinophilic asthma patients. Furthermore, expression values of hsa-miR-26a-1-3p correlated inversely with peripheral blood eosinophil count, and hsa-miR-376a-3p expression values correlated with FeNO values and the number of exacerbations. Additionally, in silico pathway enrichment analysis revealed that these 2 miRNAs regulate signaling pathways associated with the pathogenesis of asthma. CONCLUSIONS: hsa-miR-26a-1-3p and hsa-miR-376a-3p could be used to differentiate between eosinophilic and noneosinophilic asthma.


Assuntos
Asma , MicroRNAs , Humanos , MicroRNAs/genética , Sequenciamento de Nucleotídeos em Larga Escala , Biomarcadores , Fenótipo , Asma/diagnóstico , Asma/genética
7.
J. investig. allergol. clin. immunol ; 32(6): 471-478, 2022. graf
Artigo em Inglês | IBECS | ID: ibc-213398

RESUMO

Background: Asthma is a chronic inflammatory condition of the airways with a complex pathophysiology. Stratification of asthma subtypes into phenotypes and endotypes should move the field forward, making treatment more effective and personalized. Eosinophils are the key inflammatory cells involved in severe eosinophilic asthma. Given the health threat posed by eosinophilic asthma, there is a need for reliable biomarkers to identify affected patients and treat them properly with novel biologics. microRNAs (miRNAs) are a promising diagnostic tool. Objective: The aim of this study was to identify serum miRNAs that can phenotype asthma patients. Methods: Serum miRNAs of patients with eosinophilic asthma (N=40) and patients with noneosinophilic asthma (N=36) were evaluated using next-generation sequencing, specifically miRNAs-seq, and selected miRNAs were validated using RT-qPCR. Pathway enrichment analysis of deregulated miRNAs was performed. Results: Next-generation sequencing revealed 15 miRNAs that were expressed differentially between eosinophilic and noneosinophilic asthma patients, although no differences were observed in the miRNome between atopic and nonatopic asthma patients. Of the 15 miRNAs expressed differentially between eosinophilic and noneosinophilic asthma patients, hsa-miR-26a-1-3p and hsa-miR-376a-3p were validated by RT-qPCR. Expression levels of these 2 miRNAs were higher in eosinophilic than in noneosinophilic asthma patients. Furthermore, expression values of hsa-miR-26a-1-3p correlated inversely with peripheral blood eosinophil count, and hsa-miR-376a-3p expression values correlated with FeNO values and the number of exacerbations. Additionally, in silico pathway enrichment analysis revealed that these 2 miRNAs regulate signaling pathways associated with the pathogenesis of asthma. Conclusion: hsa-miR-26a-1-3p and hsa-miR-376a-3p could be used to differentiate between eosinophilic and noneosinophilic asthma (AU)


Assuntos
Humanos , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , MicroRNAs/sangue , Asma/sangue , Asma/genética , Fenótipo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Biomarcadores/sangue , Estudos de Coortes
9.
J Investig Allergol Clin Immunol ; 31(2): 94-107, 2021 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-32540792

RESUMO

Eosinophils were discovered more than 140 years ago. These polymorphonuclear leukocytes have a very active metabolism and contain numerous intracellular secretory granules that enable multiple effects on both health and disease status. Classically, eosinophils have been considered important immune cells in the pathogenesis of inflammatory processes (eg, parasitic helminth infections) and allergic or pulmonary diseases (eg, asthma) and are always associated with a type 2 immune response. Furthermore, in recent years, eosinophils have been linked to the immune response by conferring host protection against fungi, bacteria, and viruses, which they recognize through several molecules, such as toll-like receptors and the retinoic acid-inducible gene 1-like receptor. The immune protection provided by eosinophils is exerted through multiple mechanisms and properties. Eosinophils contain numerous cytoplasmatic granules that release cationic proteins, cytokines, chemokines, and other molecules, all of which contribute to their functioning. In addition to the competence of eosinophils as effector cells, their capabilities as antigen-presenting cells enable them to act in multiple situations, thus promoting diverse aspects of the immune response. This review summarizes various aspects of eosinophil biology, with emphasis on the mechanisms used and roles played by eosinophils in host defence against viral infections and response to vaccines. The review focuses on respiratory viruses, such as the new coronavirus, SARS-CoV-2.


Assuntos
COVID-19/imunologia , Eosinófilos/imunologia , SARS-CoV-2 , Animais , Humanos
10.
J. investig. allergol. clin. immunol ; 31(2): 94-107, 2021. ilus
Artigo em Inglês | IBECS | ID: ibc-215182

RESUMO

Eosinophils were discovered more than 140 years ago. These polymorphonuclear leukocytes have a very active metabolism and contain numerous intracellular secretory granules that enable multiple effects on both health and disease status. Classically, eosinophils have been considered important immune cells in the pathogenesis of inflammatory processes (eg, parasitic helminth infections) and allergic or pulmonary diseases (eg, asthma) and are always associated with a type 2 immune response. Furthermore, in recent years, eosinophils have been linked to the immune response by conferring host protection against fungi, bacteria, and viruses, which they recognize through several molecules, such as toll-like receptors and the retinoic acid–inducible gene 1–like receptor. The immune protection provided by eosinophils is exerted through multiple mechanisms and properties. Eosinophils contain numerous cytoplasmatic granules that release cationic proteins, cytokines, chemokines, and other molecules, all of which contribute to their functioning. In addition to the competence of eosinophils as effector cells, their capabilities as antigen-presenting cells enable them to act in multiple situations, thus promoting diverse aspects of the immune response. This review summarizes various aspects of eosinophil biology, with emphasis on the mechanisms used and roles played by eosinophils in host defence against viral infections and response to vaccines. The review focuses on respiratory viruses, such as the new coronavirus, SARS-CoV-2. (AU)


Los eosinófilos fueron descubiertos hace más de 140 años. Este leucocito polimorfonuclear tiene un metabolismo muy activo y contiene numerosos gránulos secretores intracelulares que le permiten ejercer múltiples funciones tanto en el estado no patológico como en el de la enfermedad. Clásicamente, los eosinófilos se han considerado como importantes células inmunes en la patogénesis de procesos inflamatorios tales como infecciones parasitarias por helmintos y enfermedades alérgicas y/o pulmonares como el asma, las cuales están asociadas a una respuesta inmune tipo 2. Además, en los últimos años, los eosinófilos también han sido relacionados con la respuesta inmunológica que confiere protección al huésped contra hongos, bacterias y virus, reconociéndolos a través de varias moléculas como los receptores tipo Toll (TLR) o los receptores parecidos al gen inducible por ácido retinoico 1 (RIG-1) o RLR. La protección inmune es ejercida a través de los múltiples mecanismos y propiedades características de estas células. Contienen numerosos gránulos citoplasmáticos que liberan proteínas catiónicas, citocinas, quimiocinas y otras moléculas que contribuyen a estas funciones. Además de su competencia como células efectoras, sus capacidades como célula presentadora de antígeno les permite actuar en múltiples situaciones, promoviendo diversos aspectos de la respuesta inmune. En esta revisión se resumen diversos aspectos de la biología de los eosinófilos y, principalmente, se repasan los mecanismos y funciones que desempeñan estas células en la defensa del huésped contra las infecciones por virus, así como la respuesta desencadenada por las vacunas víricas, focalizando la atención en los virus respiratorios como el nuevo coronavirus SARS-CoV-2. (AU)


Assuntos
Humanos , Masculino , Feminino , Anafilaxia/etiologia , Mastocitose , Infecções por Coronavirus/prevenção & controle , Infecções por Coronavirus/complicações , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/imunologia , Vacinas Sintéticas/efeitos adversos , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave , Anafilaxia/prevenção & controle , Excipientes/efeitos adversos , Triptases/efeitos adversos , Vacinação/efeitos adversos
13.
J Pediatr Urol ; 15(5): 520.e1-520.e8, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31405798

RESUMO

AIM OF THE STUDY: Endocrine-disrupting chemicals (EDCs) are exogenous agents that are capable of altering the endocrine system functions, including the regulation of developmental processes. The aim of this study was to investigate the association between EDC exposure and other parental factors in the etiology of hypospadias and cryptorchidism. METHODS: A case-control study was conducted. Cases (n = 210) were infants aged between 6 months and 14 years diagnosed with hypospadias or cryptorchidism who attended the authors' hospital over a period of 18 months, and controls (n = 210) were infants within the same range of age and without any urological disorders who attended the outpatient clinic of the same hospital during the same time period. Their selection was independent of exposures. Data on parental occupational exposure to EDCs and other sociodemographic variables were collected through face-to-face interviews and systematically for both cases and controls. Crude and adjusted odds ratios (ORs) were estimated to control for confounding with their 95% confidence interval (CI) by means of logistic regressions. Specifically, three final models of a dichotomous outcome were constructed: one for cryptorchidism, one for hypospadias, and the third considering both malformations together. The Hosmer-Lemeshow test was used to assess the goodness of fit of the models. Their discriminatory accuracy (DA) was ascertained by estimating their areas under the receiver operating characteristic curves area under the curve (AUC) along with their 95% CI. RESULTS: Associations were found between advanced maternal age (OR adjusted = 1.82; 95% CI: 1.14-2.92), mother's consumption of anti-abortives (OR = 5.40; 95% CI: 1.40-38.5) and other drugs (OR = 2.02; 95% CI: 1.31-3.16) during pregnancy, maternal and paternal occupational exposure to EDCs (OR = 4.08; 95% CI: 2.03-8.96 and OR = 3.90; 95% CI: 2.41-6.48, respectively), fathers smoking (OR = 2.0; 95% CI: 1.33-2.99), and fathers with urological disorders (OR = 2.31; 95% CI: 1.15-4.90). Maternal and paternal high educational level could be protective of cryptorchidism (OR = 0.47; 95% CI: 0.28-0.76 and OR = 0.63; 95% CI: 0.42-0.93, respectively). The DA of the models for the whole sample (AUC = 0.75; 95% CI: 0.70-0.79) for cryptorchidism (AUC = 0.76; 95% CI: 0.71-0.82) and for hypospadias (AUC = 0.75; 95% CI: 0.69-0.81) was moderately high. CONCLUSIONS: Advanced age, some parental occupational exposure to EDCs, some drug consumption, smoking, and the father's history of urological disorders may increase risk and predict the developments of these malformations. Studies with higher samples sizes are needed to assess associations between individual EDC occupational exposures and drugs and these malformations.


Assuntos
Criptorquidismo/etiologia , Disruptores Endócrinos/efeitos adversos , Hipospadia/etiologia , Exposição Materna/efeitos adversos , Exposição Ocupacional/efeitos adversos , Exposição Paterna/efeitos adversos , Medição de Risco/métodos , Adolescente , Adulto , Estudos de Casos e Controles , Criança , Pré-Escolar , Criptorquidismo/epidemiologia , Feminino , Humanos , Hipospadia/epidemiologia , Incidência , Lactente , Masculino , Fatores de Risco , Espanha/epidemiologia
17.
J Investig Allergol Clin Immunol ; 28(5): 289-304, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30059011

RESUMO

Eosinophils are terminal polymorphonuclear cells with a high number of cytoplasmic granules that originate in bone marrow. Some are exosomes, which contain multiple molecules, such as specific eosinophilic proteins, cytokines, chemokines, enzymes, and lipid mediators that contribute to the effector role of these cells. Moreover, exosomes present a large number of receptors that allow them to interact with multiple cell types. Eosinophils play an important role in defense against infestations and are a key element in asthma and allergic diseases. Eosinophils are recruited to the inflamed area in response to stimuli, modulating the immune response through the release to the extracellular medium of their granule-derived content. Various mechanisms of degranulation have been identified. Polymorphonuclear leukocytes contain multivesicular bodies that generate exosomes that are secreted into the extracellular environment. Eosinophilic exosomes participate in multiple processes and mechanisms. Eosinophils participate actively in asthma and are hallmarks of the disease. The cells migrate to the inflammatory focus and contribute to epithelial damage and airway remodeling. Given their relevance in this pathology, new therapeutic tools have been developed that target mainly eosinophils and their receptors. In this manuscript, we provide a global, updated vision of the biology of eosinophils and the role of eosinophils in respiratory diseases, particularly asthma. We also summarize asthma treatments linked to eosinophils and new therapeutic strategies based on biological products in which eosinophils and their receptors are the main targets.


Assuntos
Eosinófilos/imunologia , Animais , Asma/imunologia , Quimiocinas/imunologia , Citocinas/imunologia , Humanos , Hipersensibilidade/imunologia , Inflamação/imunologia
18.
Clin Exp Allergy ; 48(9): 1173-1185, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29451337

RESUMO

BACKGROUND: Eosinophils, a central factor in asthma pathogenesis, have the ability to secrete exosomes. However, the precise role played by exosomes in the biological processes leading up to asthma has not been fully defined. OBJECTIVE: We hypothesized that exosomes released by eosinophils contribute to asthma pathogenesis by activating structural lung cells. METHODS: Eosinophils from asthmatic patients and healthy volunteers were purified from peripheral blood, and exosomes were isolated from eosinophils of asthmatic and healthy individuals. All experiments were performed with eosinophil-derived exosomes from healthy and asthmatic subjects. Epithelial damage was evaluated using primary small airway epithelial cell lines through 2 types of apoptosis assays, that is, flow cytometry and TUNEL assay with confocal microscopy. Additionally, the epithelial repair was analysed by performing wound healing assays with epithelial cells. Functional studies such as proliferation and inhibition-proliferation assays were carried out in primary bronchial smooth muscle cell lines. Also, gene expression analysis of pro-inflammatory molecules was evaluated by real-time PCR on epithelial and muscle cells. Lastly, protein expression of epithelial and muscle cell signalling factors was estimated by Western blot. RESULTS: Asthmatic eosinophil-derived exosomes induced an increase in epithelial cell apoptosis at 24 hour and 48 hour, impeding wound closure. In addition, muscle cell proliferation was increased at 72 hours after exosome addition and was linked with higher phosphorylation of ERK1/2. We also found higher expression of several genes when both cell types were cultured in the presence of exosomes from asthmatics: CCR3 and VEGFA in muscle cells, and CCL26, TNF and POSTN in epithelial cells. Healthy eosinophil-derived exosomes did not exert any effect over these cell types. CONCLUSIONS AND CLINICAL RELEVANCE: Eosinophil-derived exosomes from asthmatic patients participate actively in the development of the pathological features of asthma via structural lung cells.


Assuntos
Remodelação das Vias Aéreas , Asma/etiologia , Asma/metabolismo , Eosinófilos/imunologia , Eosinófilos/metabolismo , Exossomos/metabolismo , Adulto , Apoptose , Asma/patologia , Biomarcadores , Estudos de Casos e Controles , Citocinas/metabolismo , Feminino , Fibrose , Humanos , Janus Quinases/metabolismo , Masculino , Pessoa de Meia-Idade , Miócitos de Músculo Liso/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Mucosa Respiratória/imunologia , Mucosa Respiratória/metabolismo , Mucosa Respiratória/patologia , Fatores de Transcrição STAT/metabolismo , Cicatrização , Adulto Jovem
19.
J Visc Surg ; 155(3): 173-181, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29396112

RESUMO

Management of functional consequences after pancreatic resection has become a new therapeutic challenge. The goal of our study is to evaluate the risk factors for exocrine (ExoPI) and endocrine (EndoPI) pancreatic insufficiency after pancreatic surgery and to establish a predictive model for their onset. PATIENTS AND METHODS: Between January 1, 2014 and June 19, 2015, 91 consecutive patients undergoing pancreatoduodenectomy (PD) or left pancreatectomy (LP) (72% and 28%, respectively) were followed prospectively. ExoPI was defined as fecal elastase content<200µg per gram of feces while EndoPI was defined as fasting glucose>126mg/dL or aggravation of preexisting diabetes. The volume of residual pancreas was measured according to the same principles as liver volumetry. RESULTS: The ExoPI and EndoPI rates at 6 months were 75.9% and 30.8%, respectively. The rate of ExoPI after PD was statistically significantly higher than after LP (98% vs. 21%; P<0.001), while the rate of EndoPI was lower after PD vs. LP, but this difference did not reach statistical significance (28% vs. 38.5%; P=0.412). There was no statistically significant difference in ExoPI found between pancreatico-gastrostomy (PG) and pancreatico-jejunostomy (PJ) (100% vs. 98%; P=1.000). Remnant pancreatic volume less than 39.5% was predictive of ExoPI. CONCLUSION: ExoPI occurs quasi-systematically after PD irrespective of the reconstruction scheme. The rate of EndoPI did not differ between PD and LP.


Assuntos
Doenças do Sistema Endócrino/etiologia , Insuficiência Pancreática Exócrina/etiologia , Pancreatectomia , Pancreaticoduodenectomia , Complicações Pós-Operatórias/etiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Doenças do Sistema Endócrino/diagnóstico , Doenças do Sistema Endócrino/epidemiologia , Insuficiência Pancreática Exócrina/diagnóstico , Insuficiência Pancreática Exócrina/epidemiologia , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/epidemiologia , Estudos Prospectivos , Fatores de Risco , Adulto Jovem
20.
J. investig. allergol. clin. immunol ; 28(5): 289-304, 2018. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-174530

RESUMO

Eosinophils are terminal polymorphonuclear cells with a high number of cytoplasmic granules that originate in bone marrow. Some are exosomes, which contain multiple molecules, such as specific eosinophilic proteins, cytokines, chemokines, enzymes, and lipid mediators that contribute to the effector role of these cells. Moreover, exosomes present a large number of receptors that allow them to interact with multiple cell types. Eosinophils play an important role in defense against infestations and are a key element in asthma and allergic diseases. Eosinophils are recruited to the inflamed area in response to stimuli, modulating the immune response through the release to the extracellular medium of their granule-derived content. Various mechanisms of degranulation have been identified. Polymorphonuclear leukocytes contain multivesicular bodies that generate exosomes that are secreted into the extracellular environment. Eosinophilic exosomes participate in multiple processes and mechanisms. Eosinophils participa e actively in asthma and are hallmarks of the disease. The cells migrate to the inflammatory focus and contribute to epithelial damage and airway remodeling. Given their relevance in this pathology, new therapeutic tools have been developed that target mainly eosinophils and their receptors. In this manuscript, we provide a global, updated vision of the biology of eosinophils and the role of eosinophils in respiratory diseases, particularly asthma. We also summarize asthma treatments linked to eosinophils and new therapeutic strategies based on biological products in which eosinophils and their receptors are the main targets


Los eosinófilos son células polimorfonucleares terminales originadas en la médula ósea con un número importante de gránulos citoplasmáticos, algunos de los cuales son exosomas, que contienen múltiples moléculas como proteínas eosinofílicas específicas, citocinas, quimiocinas, enzimas y mediadores lipídicos que contribuyen al papel efector de estas células. Además, presentan una gran cantidad de receptores que les permiten interactuar con múltiples tipos celulares. Los eosinófilos desempeñan un papel importante en la defensa contra las infestaciones y son un elemento clave en el asma y las enfermedades alérgicas. Los eosinófilos se reclutan hacia el área de inflamación en respuesta a varios estímulos, modulando la respuesta inmune a través de la liberación al medio extracelular del contenido derivado de sus gránulos, existiendo diferentes mecanismos de degranulación. Estos leucocitos polimorfonucleares contienen cuerpos multivesiculares que generan exosomas que se secretan al ambiente extracelular. Estos exosomas eosinofílicos participan en múltiples procesos y mecanismos. En relación con la enfermedad asmática, los eosinófilos participan activamente en los elementos distintivos de esta patología. Estas células migran al foco inflamatorio y contribuyen al daño del epitelio y a la remodelación de las vías respiratorias. Debido a su relevancia en esta patología, se han desarrollado nuevas herramientas terapéuticas, siendo los eosinófilos y sus receptores sus objetivos principales. En este manuscrito, proporcionamos una visión global y actualizada sobre la biología de los eosinófilos, su papel en las enfermedades respiratorias, centrando nuestra atención en la patología asmática, así como un resumen de los tratamientos y nuevas estrategias terapéuticas basadas en tratamientos biológicos en los que los eosinófilos y sus receptores son los principales objetivos


Assuntos
Humanos , Eosinofilia/imunologia , Eosinófilos/imunologia , Exossomos/imunologia , Asma/imunologia , Hipersensibilidade Respiratória/imunologia , Terapia Biológica , Produtos Biológicos/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...